Patients and the payers (usually employers) who cover the cost of drug benefits both benefit from direct-to-patient models.
But direct-to-patient drug sales can help with make more affordable, argue HealthDyne’s David Skomo and Sarah Thomas ...
A high-touch specialty pharmacy program that combines pharmacist support, telehealth and value-based care reduced medical ...
Retail blockbusters, then specialty drugs. Now a new era of mega-blockbusters | Asembia AXS26 Summit
The pharmaceutical industry is entering an era of mega-blockbusters, drugs with annual sales of $10 billion or more, that ...
Frequent CGM use ties to bigger A1c drops in type 2 diabetes, even across GLP-1, SGLT2, and insulin regimens. In this episode ...
PSG’s research found that payers are placing more attention on specialty drugs covered under the medical benefit, showing ...
Andrew Mellin, M.D., discusses Surescripts’ pilot program for prior authorization system, which pulls clinical data from EHRs ...
Bispecific antibodies are currently approved as late-line therapy, but they are moving up to earlier lines “as they prove ...
Provider groups, especially community oncologists, are worried that drug prices negotiated under the IRA will drastically ...
The 340B Drug Pricing Program has become a central force in the U.S. drug market, allowing certain hospitals and clinics to ...
Teclistamab has a clear advantage because it was the first bispecific antibody to be approved, said Adams. Route of ...
ADVI Health’s Lindsay Greenleaf discusses how most-favored-nation drug pricing is playing out among specialty drugs. Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results